These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 24736462

  • 1. Endothelial progenitor cells and response to ranibizumab in age-related macular degeneration.
    Scotti F, Maestroni A, Palini A, Introini U, Setaccioli M, Lorenzi M, Zerbini G.
    Retina; 2014 Sep; 34(9):1802-10. PubMed ID: 24736462
    [Abstract] [Full Text] [Related]

  • 2. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
    Grierson R, Meyer-Rüsenberg B, Kunst F, Berna MJ, Richard G, Thill M.
    J Ocul Pharmacol Ther; 2013 Sep; 29(6):530-8. PubMed ID: 23573802
    [Abstract] [Full Text] [Related]

  • 3. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK, Moon HJ.
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [Abstract] [Full Text] [Related]

  • 4. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.
    Machalińska A, Paczkowska E, Pabin T, Safranow K, Karczewicz D, Machaliński B.
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):471-5. PubMed ID: 21830945
    [Abstract] [Full Text] [Related]

  • 5. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
    You JY, Chung H, Kim HC.
    Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
    [Abstract] [Full Text] [Related]

  • 7. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
    Erol MK, Ozdemir O, Coban DT, Ceran BB, Bulut M.
    Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
    [Abstract] [Full Text] [Related]

  • 8. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.
    Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
    [Abstract] [Full Text] [Related]

  • 9. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization.
    Krishnan R, Goverdhan S, Lochhead J.
    Clin Exp Ophthalmol; 2009 May; 37(4):384-8. PubMed ID: 19594565
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S.
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
    Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, Rouvas AA.
    Ophthalmologica; 2012 Oct; 228(2):93-101. PubMed ID: 22571933
    [Abstract] [Full Text] [Related]

  • 12. Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration.
    Shin HJ, Chung H, Kim HC.
    Retina; 2013 May; 33(5):964-70. PubMed ID: 23348865
    [Abstract] [Full Text] [Related]

  • 13. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY, Kwon KY, Byeon SH.
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
    Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A, EXCITE Study Group.
    Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
    [Abstract] [Full Text] [Related]

  • 15. Circulating endothelial and progenitor cells in age-related macular degeneration.
    Mucciolo DP, Marcucci R, Sodi A, Cesari F, Murro V, Rogolino A, Rizzo S, Giusti B, Virgili G, Prisco D, Gori AM.
    Eur J Ophthalmol; 2020 Sep; 30(5):956-965. PubMed ID: 31328962
    [Abstract] [Full Text] [Related]

  • 16. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 17. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 18. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
    Bressler SB.
    Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
    [Abstract] [Full Text] [Related]

  • 19. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
    Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B, MARINA and ANCHOR Study Groups.
    Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B, Adewoyin T, Patel SK, Sivaprasad S.
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.